Today, January 13, 2009, their are several stocks gainers that are active in pre market trading. Check out today's biggest gainers and the Top Stocks for 2009.
Pre Market Gainers - 1/13/09
ZymoGenetics ( ZGEN ) - $4.69 Up 50% - Bristol Myers will pay tiny biotechnology company ZymoGenetics $105 million to license, develop and sell its experimental new form of interferon to treat hepatitis C.
NexMed ( NEXM ) - $0.28 Up 34% - This stock is going up on no news
Elan ( ELN ) - $9.00 Up 12% - ELN, founder of the drug Tysabri, is muling a possible sale or merger of the company.
Citigroup ( C ) - $5.06 Down 9.82% - Citigroup is gapping down 9.8% this morning after falling nearly 20% yesterday!
For the latest updates on the stock market, visit, http://daytradingstockblog.blogspot.com/ or Subscribe for Free
Showing posts with label eln - elan. Show all posts
Showing posts with label eln - elan. Show all posts
Tuesday, January 13, 2009
Tuesday, August 26, 2008
Elan ( ELN ) Biogen ( BIIB ) Tysabri Update - MS Drug 8/26/08
Last night, Biogen ( BIIB ) came out with an update regard the multiple sclerosis drug, Tysabri, which they are co developing with Elan ( ELN ) corporation.
The FDA is working with the companies to amend the product labeling to inform patients of the two cases. A company spokeswoman said the updated label will be based on the two cases, which the company had confirmed in late July.
The patients had been taking the drug, as a sole treatment for multiple sclerosis, for more than a year, according to an alert the FDA issued to health-care professionals that was posted on the agency's Web site Monday.
This is great news for both companies, I expect them to move high in the coming weeks and months. If the patients in Europe that has this brain disorder die however; it could have negative implications on the these two stocks.
The FDA is working with the companies to amend the product labeling to inform patients of the two cases. A company spokeswoman said the updated label will be based on the two cases, which the company had confirmed in late July.
The patients had been taking the drug, as a sole treatment for multiple sclerosis, for more than a year, according to an alert the FDA issued to health-care professionals that was posted on the agency's Web site Monday.
This is great news for both companies, I expect them to move high in the coming weeks and months. If the patients in Europe that has this brain disorder die however; it could have negative implications on the these two stocks.
Subscribe to:
Posts (Atom)